Nordic Mubio sought to acquire companies and engaged Pivotal Scientific for M&A Buy-Side services. We created a long list and then a short list of potential target companies for Nordic Mubio to consider. After identifying a suitable target, we conducted commercial due diligence (CDD) and managed the entire process through to completion, ensuring a smooth and successful acquisition.
Acquired in 2018, Nordic-MUbio is the new home for Biologo’s range of monoclonal and polyclonal antibodies. Biologo-branded reagents include primary antibodies for life science research related to advanced glycation end-products (AGE), the extracellular matrix and various cancers. Highly validated and widely cited, they are suitable for use in applications such as immunohistochemistry, enzyme-linked immunosorbent assay (ELISA) and western blotting.
Published: March 1, 2018
Biologo acquired by Nordic-MUbio
Pivotal Transactions
